Balloon pulmonary angioplasty (BPA) to treat chronic thromboembolic pulmonary hypertension (CTEPH) is generally reserved for distal obstruction precluding pulmonary endarterectomy (PEA) but can be used in patients with proximal disease who are at high surgical risk or refuse surgery. This single-center retrospective study compared BPA efficacy in patients with proximal versus distal CTEPH.
Webinar presentations: Autophagy and BMPR2 receptor degradation as the cause of PAH; BMPR1A promotes ID2-ZEB1 interaction to suppress endothelial to mesenchymal transition in PAH; Cardiovascular and pulmonary phenotypes for single and double knockout mice deficient in BMP9 and BMP10; BMPR2 – When and where the animal models match patient disease
Treatment modalities for pulmonary arterial hypertension (PAH) improve quality of life and walk distance. However, none of these therapies alter the structural/functional pulmonary vascular integrity that results in vascular remodeling. PAH smooth muscle cells share biological characteristics with cancer cells, which may be potential therapeutic targets for PAH.
'Clinical aspects' is part of the Microbes Virtual Symposium series by the iPVD, a global education programme that highlights top-notch research on inflammation and infectious PVD.
The present study aimed to evaluate the efficacy of long-term riociguat sequentially combined with balloon pulmonary angioplasty (BPA) for patients with inoperable chronic thromboembolic pulmonary hypertension (CTEPH).
COVID-19 associates with a hypercoagulant state and an increased risk for venous thromboembolic events (VTEs). Whether severe COVID-19 infection requiring extracorporeal membrane oxygenation (ECMO) support might lead to chronic pulmonary perfusion abnormalities and chronic thromboembolic pulmonary disease/hypertension remains unclear.
Therapies for inoperable chronic thromboembolic pulmonary hypertension (CTEPH) include balloon pulmonary angioplasty (BPA) and PH-specific medical therapy. This study compares survival and its predictors before and after the introduction of BPA. BPA was independently associated with survival; however, there was no difference in overall survival between the two cohorts.
In pulmonary hypertension (PH) associated with chronic lung disease (CLD), identifying patients who would benefit from pulmonary vasodilators is a significant clinical challenge because the presence of PH is associated with poorer survival. This study evaluated the severity of pulmonary circulation impairment in patients with CLD-PH using pulmonary perfusion single-photon emission computed tomography/computed tomography (SPECT/CT).
Pulmonary hypertension (PH) is a complex cardiovascular disorder characterized by elevated mean pulmonary artery pressure >20 mmHg at rest. PH is classified into five groups based on etiology, each with unique underlying causes and pathophysiological mechanisms: pulmonary arterial hypertension (PAH), PH due to left heart disease, PH due to lung disease or hypoxia, chronic thromboembolic pulmonary hypertension (CTEPH), and PH with unclear multifactorial mechanisms.
